Clinical Trials Directory

Trials / Unknown

UnknownNCT03591627

Left Atrial Thrombus on Transesophageal Echocardiography

Status
Unknown
Phase
—
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Medical University of Warsaw · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
—

Summary

The aim of the study is to assess the prevalence of left atrial thrombus in patients with atrial fibrillation (AF) or atrial flutter (AFI), in whom transesophageal echocardiography is performed before AF/AFl cardioversion or ablation.

Detailed description

Atrial fibrillation (AF) and atrial flutter (AFI) increase the risk of thromboembolic events by promoting clot formation in the left atrium (LA). Transesophageal echocardiography (TEE) is routinely used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion. So far, it has not been established what is the optimal combination of noninvasive parameters for thromboembolic risk stratification in this setting. The present study is aimed to compare the prevalence of LA thrombus in patients on different anticoagulant regimens, identify predictors of LA thrombus and validate the newly developed CHA2DS2-VASc-AF-GFR score (and to compare its predictive value in LA thrombus identification with those of the CHA2DS2-VASc and the CHADS2 scores). The study protocol all patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTransesophageal echocardiographyTransesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.

Timeline

Start date
2018-10-01
Primary completion
2019-09-30
Completion
2019-09-30
First posted
2018-07-19
Last updated
2018-11-05

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT03591627. Inclusion in this directory is not an endorsement.